clene.com (CLNN) Price to Earnings Ratio
This daily price chart for Clene Inc. (CLNN), which has a PE ratio of -2.40, illustrates the business development of its neuroprotector pipeline. Supply chain reliability is ensured by a specialized temperature regime and field protection during the transport of medications. The company's resilience to economic cycles is driven by its focus on clinical trials. High brand authority among ALS patients and shareholder confidence are based on the innovative nanocrystalline platform.
Analytical breakdowns for Clene Inc (CLNN)
- stock value and consensus price forecast:
- market capitalization details:
- book capitalization information:
- debt and solvency information:
- business earnings and investment ratios data:
CLNN - Net Income|Company Profit Forecast Clene Inc.|CLNN - P/E Multiple|Projected Price to Earnings Clene Nanomedicine|CLNN - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc.|CLNN - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Clene|CLNN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months clene.com|CLNN - Earnings per share growth in current year|Projected earnings per share growth rate for next year Clene Inc.
Summary company analysis:Clene Inc.
The P/E ratio determines the market value of a business relative to its annual net income, measuring the investment payback period and the valuation's sensitivity to financial statements. The P/E valuation trend for Clene Inc. (CLNN) on the GURU.Markets platform reflects market expectations for the company's nanoparticle patents, where high metric volatility underscores the speculative potential of biopharmaceutical developments for treating neurodegeneration.
Analysis of competing companies
Price to Earnings Ratio biogen.com (BIIB)|Price to Earnings Ratio Neurocrine Biosciences, Inc. (NBIX)|Price to Earnings Ratio RGC (Regencell Bioscience Ltd)|P/E Multiple AXSM (Axsome Therapeutics Inc)|ACADIA Corp (ACAD) - Market Cap to Earnings|XENE - Price to Earnings Ratio|VKTX (vikingtherapeutics.com) - Price to Earnings Multiple|SUPN: P/E Multiple|Market Cap to Earnings Catalyst Pharma (CPRX)|Price to Earnings Ratio DNLI|HRMY: Company Value to Net Income|P/E Multiple BHVN|Business Payback Period amylyx.com|Price to Earnings Ratio Trevi Therapeutics, Inc. TRVI|PRAX: Price to Earnings Multiple|Anavex Corp - P/E Multiple|CeriBell EEG (CBLL) - Price to Earnings Ratio|PRTA (prothena.com) - Price to Earnings Ratio|ALEC - Business Payback Period|ANNX (Annexon) - P/E Multiple|Price to Earnings Ratio Omeros Corp. (OMER)|Price to Earnings Ratio Neurogene Corp (NGNE)|Price to Earnings Ratio ACIU (AC Immune Inc)|Price to Earnings Ratio Voyager Therapeutics VYGR|NMRA: Price to Earnings Multiple|SCLX - Price to Earnings Ratio|TVGN (Tevogen Bio Holdings Inc.) - Price to Earnings Multiple|alphacognition.com (ACOG) - Price to Earnings Ratio|Price to Earnings Multiple CGTX|IKT (Inhibikase Therapeutics) - P/E Multiple|Market Cap to Earnings cassavasciences.com SAVA|Price to Earnings Ratio ASRT (Assertio Holdings, Inc.)|P/E Multiple coyatherapeutics.com (COYA)|Price to Earnings Ratio Vistagen VTGN|Company Value to Net Income OVID|ABOS - Price to Earnings Ratio|Market Cap to Earnings cervomed.com|ATHE: P/E Multiple|Price to Earnings Ratio PepGen|Price to Earnings Ratio Jupiter Neurosciences|Price to Earnings Ratio RLMD|P/E Multiple ANVS|GRCE - Market Cap to Earnings|Price to Earnings Ratio Firefly Neuroscience AIFF|KLTO: Price to Earnings Multiple|NeuroSense Therapeutics, Ltd. - P/E Multiple|Market Cap to Earnings Reviva Pharmaceuticals, Inc.|MTVA (metaviatx.com) - Price to Earnings Ratio|neuraxis.com - Company Value to Net Income|HSDT (Helius Medical Technologies, Inc.) - P/E Multiple|Passage Bio Corp (PASG) - Business Payback Period|Price to Earnings Ratio Neuphoria Therapeutics Inc. (NEUP)|Minerva - Price to Earnings Multiple|P/E Multiple ATHA (Athira Pharma, Inc.)|ADXN - Price to Earnings Ratio|ALZN: Price to Earnings Ratio|Business Payback Period Cyclerion Therapeutics CYCN|PTIX: P/E Multiple|Price to Earnings Ratio Pasithea Therapeutics Corp.|Price to Earnings Ratio Cortigent Inc|Price to Earnings Ratio ATXI|Price to Earnings Ratio BrainStorm Cell Therapeutics (BCLI)|Cara Therapeutics Inc. - Price to Earnings Multiple|Price to Earnings Ratio Chromocell Therapeutics Corporation CHRO|ELYM: Price to Earnings Multiple|ITCI - Price to Earnings Ratio|LBPH (longboardpharma.com) - Price to Earnings Multiple|MRNS: P/E Multiple|Market Cap to Earnings NKGen Biotech Inc (NKGN)|Price to Earnings Ratio NRBO|P/E Multiple Sage Therapeutics Inc|Price to Earnings Ratio Synaptogenix, Inc. (SNPX)|TRVN (trevena.com) - Company Value to Net Income|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|anewmeds.com (WENA) - Market Cap to Earnings|Cerevel - P/E Multiple
